Literature DB >> 21864812

Reference limits for N-terminal-pro-B-type natriuretic peptide in healthy individuals (from the Framingham Heart Study).

Michael G Fradley1, Martin G Larson, Susan Cheng, Elizabeth McCabe, Erin Coglianese, Ravi V Shah, Daniel Levy, Ramachandran S Vasan, Thomas J Wang.   

Abstract

N-terminal pro-B-type natriuretic peptide (NT-pro-BNP) is a commonly measured cardiovascular biomarker in ambulatory and hospital settings. Nonetheless, there are limited data regarding "normal" ranges for NT-pro-BNP in healthy subjects, despite the importance of such information for interpreting natriuretic peptide measurements. In this study, a healthy reference sample free of cardiovascular disease from the Framingham Heart Study Generation 3 cohort was examined; there were 2,285 subjects (mean age 38 years, 56% women). Plasma NT-pro-BNP levels were measured using the Roche Diagnostics Elecsys 2010 assay, and reference values (2.5th, 50th, and 97.5th quantiles) were determined using empiric and quantile regression methods. Gender, age, blood pressure, and body mass index accounted for approximately 33% of the interindividual variability in NT-pro-BNP in the reference sample. NT-pro-BNP values were substantially higher in women compared to men at every age, and levels increased with increasing age for both genders. Using quantile regression, the upper reference values (97.5th quantile) for NT-pro-BNP were 42.5 to 106.4 pg/ml in men (depending on age) and 111.0 to 215.9 pg/ml in women. Intraindividual variability was assessed in an additional 12 healthy subjects, who had serial NT-pro-BNP measurements over 1 month. Intraclass correlation was 0.85, indicating that most of the variability in NT-pro-BNP concentrations was among rather than within subjects. However, the reference change value was 100%, suggesting that small proportional differences in NT-pro-BNP could be attributable to analytic variability. In conclusion, the reference limits obtained from this large, healthy, community-based sample may aid in the evaluation of NT-pro-BNP concentrations measured for clinical and research purposes.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21864812      PMCID: PMC3209520          DOI: 10.1016/j.amjcard.2011.06.057

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  19 in total

1.  Quantile regression methods for reference growth charts.

Authors:  Ying Wei; Anneli Pere; Roger Koenker; Xuming He
Journal:  Stat Med       Date:  2006-04-30       Impact factor: 2.373

2.  Reference interval determination for N-terminal-B-type natriuretic peptide (NT-proBNP): a study in blood donors.

Authors:  Georg Hess; Stefan Runkel; Dietmar Zdunek; Walter E Hitzler
Journal:  Clin Chim Acta       Date:  2005-10       Impact factor: 3.786

3.  What is the normal range for N-terminal pro-brain natriuretic peptide? How well does this normal range screen for cardiovascular disease?

Authors:  Gavin I W Galasko; Avijit Lahiri; Sophie C Barnes; Paul Collinson; Roxy Senior
Journal:  Eur Heart J       Date:  2005-07-21       Impact factor: 29.983

4.  Associations among androgens, estrogens, and natriuretic peptides in young women: observations from the Dallas Heart Study.

Authors:  Alice Y Chang; Shuaib M Abdullah; Tulika Jain; Harold G Stanek; Sandeep R Das; Darren K McGuire; Richard J Auchus; James A de Lemos
Journal:  J Am Coll Cardiol       Date:  2006-11-13       Impact factor: 24.094

5.  Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction.

Authors:  Lisa C Costello-Boerrigter; Guido Boerrigter; Margaret M Redfield; Richard J Rodeheffer; Lynn H Urban; Douglas W Mahoney; Steven J Jacobsen; Denise M Heublein; John C Burnett
Journal:  J Am Coll Cardiol       Date:  2006-01-04       Impact factor: 24.094

6.  The Third Generation Cohort of the National Heart, Lung, and Blood Institute's Framingham Heart Study: design, recruitment, and initial examination.

Authors:  Greta Lee Splansky; Diane Corey; Qiong Yang; Larry D Atwood; L Adrienne Cupples; Emelia J Benjamin; Ralph B D'Agostino; Caroline S Fox; Martin G Larson; Joanne M Murabito; Christopher J O'Donnell; Ramachandran S Vasan; Philip A Wolf; Daniel Levy
Journal:  Am J Epidemiol       Date:  2007-03-19       Impact factor: 4.897

7.  Plasma concentrations of N-terminal brain natriuretic peptide in healthy children, adolescents, and young adults: effect of age and gender.

Authors:  T S Mir; M Flato; J Falkenberg; M Haddad; R Budden; J Weil; S Albers; S Laer
Journal:  Pediatr Cardiol       Date:  2006 Jan-Feb       Impact factor: 1.655

Review 8.  Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: the role of biologic variation in the interpretation of results.

Authors:  Alan H B Wu
Journal:  Am Heart J       Date:  2006-11       Impact factor: 4.749

9.  High intraindividual variation of B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with stable chronic heart failure.

Authors:  Sanne Bruins; M Rebecca Fokkema; Jeroen W P Römer; Mike J L Dejongste; Fey P L van der Dijs; Jody M W van den Ouweland; Frits A J Muskiet
Journal:  Clin Chem       Date:  2004-09-02       Impact factor: 8.327

10.  Attenuation of biologic compensatory action of cardiac natriuretic peptide system with aging.

Authors:  Keisuke Kawai; Katsuya Hata; Katsuji Tanaka; Yoshihisa Kubota; Ryuji Inoue; Eisaku Masuda; Toshiyuki Miyazaki; Mitsuhiro Yokoyama
Journal:  Am J Cardiol       Date:  2004-03-15       Impact factor: 2.778

View more
  47 in total

1.  Sex-specific associations of obesity and N-terminal pro-B-type natriuretic peptide levels in the general population.

Authors:  Navin Suthahar; Wouter C Meijers; Jennifer E Ho; Ron T Gansevoort; Adriaan A Voors; Peter van der Meer; Stephan J L Bakker; Stephane Heymans; Vanessa van Empel; Blanche Schroen; Pim van der Harst; Dirk J van Veldhuisen; Rudolf A de Boer
Journal:  Eur J Heart Fail       Date:  2018-06-01       Impact factor: 15.534

2.  Insulin resistance is associated with increased concentrations of NT-proBNP in rheumatoid arthritis: IL-6 as a potential mediator.

Authors:  William S Bradham; Michelle J Ormseth; Annette Oeser; Joseph F Solus; Tebeb Gebretsadik; Ayumi Shintani; C Michael Stein
Journal:  Inflammation       Date:  2014-06       Impact factor: 4.092

3.  Effects of transdermal testosterone on natriuretic peptide levels in women: a randomized placebo-controlled pilot study.

Authors:  Eleanor Lin; Elizabeth McCabe; Christopher Newton-Cheh; Kenneth Bloch; Emmanuel Buys; Thomas Wang; Karen K Miller
Journal:  Fertil Steril       Date:  2011-12-02       Impact factor: 7.329

4.  High-sensitivity troponin T and N-terminal pro-B-type natriuretic peptide (NT-proBNP) and risk of incident heart failure in patients with CKD: the Chronic Renal Insufficiency Cohort (CRIC) Study.

Authors:  Nisha Bansal; Amanda Hyre Anderson; Wei Yang; Robert H Christenson; Christopher R deFilippi; Rajat Deo; Daniel L Dries; Alan S Go; Jiang He; John W Kusek; James P Lash; Dominic Raj; Sylvia Rosas; Myles Wolf; Xiaoming Zhang; Michael G Shlipak; Harold I Feldman
Journal:  J Am Soc Nephrol       Date:  2014-10-02       Impact factor: 10.121

Review 5.  Biochemical markers of aging for longitudinal studies in humans.

Authors:  Peter M Engelfriet; Eugène H J M Jansen; H Susan J Picavet; Martijn E T Dollé
Journal:  Epidemiol Rev       Date:  2013-02-04       Impact factor: 6.222

6.  Longitudinal assessment of N-terminal pro-B-type natriuretic peptide and risk of diabetes in older adults: The cardiovascular health study.

Authors:  Erika F Brutsaert; Mary L Biggs; Joseph A Delaney; Luc Djoussé; John S Gottdiener; Joachim H Ix; Francis Kim; Kenneth J Mukamal; David S Siscovick; Russell P Tracy; Ian H de Boer; Christopher R deFilippi; Jorge R Kizer
Journal:  Metabolism       Date:  2016-06-24       Impact factor: 8.694

7.  Sex differences in presentation, management, and outcomes among patients hospitalized with acute pulmonary embolism.

Authors:  Abby M Pribish; Sebastian E Beyer; Anna K Krawisz; Ido Weinberg; Brett J Carroll; Eric A Secemsky
Journal:  Vasc Med       Date:  2020-11-17       Impact factor: 3.239

8.  Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study.

Authors:  Erin E Coglianese; Martin G Larson; Ramachandran S Vasan; Jennifer E Ho; Anahita Ghorbani; Elizabeth L McCabe; Susan Cheng; Michael G Fradley; Dana Kretschman; Wei Gao; George O'Connor; Thomas J Wang; James L Januzzi
Journal:  Clin Chem       Date:  2012-10-11       Impact factor: 8.327

9.  Biomarkers of chronic cardiac injury and hemodynamic stress identify a malignant phenotype of left ventricular hypertrophy in the general population.

Authors:  Ian J Neeland; Mark H Drazner; Jarett D Berry; Colby R Ayers; Christopher deFilippi; Stephen L Seliger; Vijay Nambi; Darren K McGuire; Torbjørn Omland; James A de Lemos
Journal:  J Am Coll Cardiol       Date:  2012-12-05       Impact factor: 24.094

10.  Pharmacokinetic-pharmacodynamic modelling of acute N-terminal pro B-type natriuretic peptide after doxorubicin infusion in breast cancer.

Authors:  Shuang Liang; Richard C Brundage; Pamala A Jacobson; Anne Blaes; Mark N Kirstein
Journal:  Br J Clin Pharmacol       Date:  2016-06-03       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.